Gene expression of Interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy.
Disease modifying anti-rheumatic drugs
Gene expression
Interleukin-18
Rheumatoid arthritis
Journal
Pakistan journal of medical sciences
ISSN: 1682-024X
Titre abrégé: Pak J Med Sci
Pays: Pakistan
ID NLM: 100913117
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
2
7
2019
pubmed:
2
7
2019
medline:
2
7
2019
Statut:
ppublish
Résumé
The hallmark of rheumatoid arthritis is the inflammation that is mediated by the macrophages and monocytes that cause release of pro-inflammatory cytokines like interleukin-18. It is highly expressed in serum of patients suffering from rheumatoid arthritis and has a positive association with disease activity. The aim of this study was to analyze the gene expression of interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy. The cross sectional comparative study is conducted at Department of Biochemistry and Molecular Biology and Center for Research in Experimental and Applied Medicine (CREAM-1Lab), Army Medical College, Rawalpindi, in collaboration with Rheumatology Department, Military Hospital, Rawalpindi. Study was conducted on two groups consisting of Group-I of rheumatoid arthritis patients on diseases modifying anti-rheumatic drugs and control Group-II comprising of normal healthy individuals. Non-probability purposive sampling was done from patients and controls. The duration of study was one year i-e from November 2015 to November 2016. Relative quantification of gene expression of interleukin-18 was done by Real time PCR using ∆∆CT method. Expression analysis for interleukin-18 showed down regulation of gene in rheumatoid arthritis patients as compared to controls. Interleukin-18 gene shows down regulation in rheumatoid arthritis patients on disease modifying anti-rheumatic drugs therapy.
Sections du résumé
BACKGROUND & OBJECTIVES
OBJECTIVE
The hallmark of rheumatoid arthritis is the inflammation that is mediated by the macrophages and monocytes that cause release of pro-inflammatory cytokines like interleukin-18. It is highly expressed in serum of patients suffering from rheumatoid arthritis and has a positive association with disease activity. The aim of this study was to analyze the gene expression of interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy.
METHODS
METHODS
The cross sectional comparative study is conducted at Department of Biochemistry and Molecular Biology and Center for Research in Experimental and Applied Medicine (CREAM-1Lab), Army Medical College, Rawalpindi, in collaboration with Rheumatology Department, Military Hospital, Rawalpindi. Study was conducted on two groups consisting of Group-I of rheumatoid arthritis patients on diseases modifying anti-rheumatic drugs and control Group-II comprising of normal healthy individuals. Non-probability purposive sampling was done from patients and controls. The duration of study was one year i-e from November 2015 to November 2016. Relative quantification of gene expression of interleukin-18 was done by Real time PCR using ∆∆CT method.
RESULTS
RESULTS
Expression analysis for interleukin-18 showed down regulation of gene in rheumatoid arthritis patients as compared to controls.
CONCLUSION
CONCLUSIONS
Interleukin-18 gene shows down regulation in rheumatoid arthritis patients on disease modifying anti-rheumatic drugs therapy.
Identifiants
pubmed: 31258598
doi: 10.12669/pjms.35.3.1070
pii: PJMS-35-802
pmc: PMC6572992
doi:
Types de publication
Journal Article
Langues
eng
Pagination
802-806Déclaration de conflit d'intérêts
Conflict of Interest: The authors of this study reported no conflict of interest.
Références
Rheumatology (Oxford). 2001 Mar;40(3):302-9
pubmed: 11285378
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Ann Rheum Dis. 2002 Aug;61(8):726-9
pubmed: 12117681
Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii48-50
pubmed: 14532149
Arthritis Rheum. 2004 Dec;50(12):3856-65
pubmed: 15593217
Nat Clin Pract Rheumatol. 2007 Aug;3(8):450-8; quiz, following 478
pubmed: 17664952
Clin Exp Med. 2009 Sep;9(3):215-21
pubmed: 19225717
Br Med Bull. 2010;94:201-14
pubmed: 20200013
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Arthritis Rheum. 2011 Mar;63(3):633-9
pubmed: 21360492
J Pak Med Assoc. 2011 Feb;61(2):123-6
pubmed: 21375157
Arthritis Res Ther. 2011 Mar 24;13(2):R52
pubmed: 21435242
Immunogenetics. 2011 Aug;63(8):459-66
pubmed: 21556860
J Interferon Cytokine Res. 2011 Oct;31(10):745-51
pubmed: 21864160
Mayo Clin Proc. 2012 Jul;87(7):659-73
pubmed: 22766086
Rheum Dis Clin North Am. 2012 May;38(2):405-26
pubmed: 22819092
Front Immunol. 2012 Dec 04;3:366
pubmed: 23264777
Clin Rev Allergy Immunol. 2013 Oct;45(2):170-9
pubmed: 23288628
Nat Rev Rheumatol. 2013 Mar;9(3):141-53
pubmed: 23381558
Egypt J Immunol. 2012;19(2):13-24
pubmed: 23885403
Front Immunol. 2013 Oct 08;4:289
pubmed: 24115947
Ann Rheum Dis. 2014 Mar;73(3):492-509
pubmed: 24161836
World J Orthop. 2014 Sep 18;5(4):516-36
pubmed: 25232528
Sci Rep. 2016 May 06;6:25481
pubmed: 27149934